Published in J Virol on September 01, 1998
RNA polymerase is poised for activation across the genome. Nat Genet (2007) 9.57
P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol (2000) 5.64
The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev (1998) 4.38
NELF-mediated stalling of Pol II can enhance gene expression by blocking promoter-proximal nucleosome assembly. Genes Dev (2008) 3.69
Domains in the SPT5 protein that modulate its transcriptional regulatory properties. Mol Cell Biol (2000) 2.74
The RNA polymerase II CTD coordinates transcription and RNA processing. Genes Dev (2012) 2.55
Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. Mol Cell Biol (2004) 2.49
Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature (2010) 2.08
Tat competes with HEXIM1 to increase the active pool of P-TEFb for HIV-1 transcription. Nucleic Acids Res (2007) 2.02
CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA. Mol Cell Biol (2000) 1.89
Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb Perspect Med (2012) 1.88
Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T. Proc Natl Acad Sci U S A (1999) 1.87
Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. Proc Natl Acad Sci U S A (1999) 1.82
ICP22 and the UL13 protein kinase are both required for herpes simplex virus-induced modification of the large subunit of RNA polymerase II. J Virol (1999) 1.73
Interaction between P-TEFb and the C-terminal domain of RNA polymerase II activates transcriptional elongation from sites upstream or downstream of target genes. Mol Cell Biol (2002) 1.68
Tat gets the "green" light on transcription initiation. Retrovirology (2005) 1.61
A model of repression: CTD analogs and PIE-1 inhibit transcriptional elongation by P-TEFb. Genes Dev (2003) 1.57
Control of stochastic gene expression by host factors at the HIV promoter. PLoS Pathog (2009) 1.50
The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol (2012) 1.50
Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4(+) T lymphocytes by combination of cytokines. J Virol (2001) 1.48
Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virology (2014) 1.45
TAR RNA loop: a scaffold for the assembly of a regulatory switch in HIV replication. Proc Natl Acad Sci U S A (2002) 1.44
Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir. J Virol (2003) 1.40
Effect of SWI/SNF chromatin remodeling complex on HIV-1 Tat activated transcription. Retrovirology (2006) 1.36
Differential acetylation of Tat coordinates its interaction with the co-activators cyclin T1 and PCAF. EMBO J (2002) 1.27
Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1). J Virol (2004) 1.26
Recruitment of human cyclin T1 to nuclear bodies through direct interaction with the PML protein. EMBO J (2003) 1.26
A novel PCR assay for quantification of HIV-1 RNA. J Virol (2013) 1.25
Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr HIV Res (2011) 1.23
Interactions between equine cyclin T1, Tat, and TAR are disrupted by a leucine-to-valine substitution found in human cyclin T1. J Virol (2000) 1.17
Acetylation of conserved lysines in the catalytic core of cyclin-dependent kinase 9 inhibits kinase activity and regulates transcription. Mol Cell Biol (2008) 1.15
Antiapoptotic function of Cdk9 (TAK/P-TEFb) in U937 promonocytic cells. J Virol (2001) 1.14
Regulation of P-TEFb elongation complex activity by CDK9 acetylation. Mol Cell Biol (2007) 1.13
Runx1 binds positive transcription elongation factor b and represses transcriptional elongation by RNA polymerase II: possible mechanism of CD4 silencing. Mol Cell Biol (2005) 1.10
Cell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator. J Virol (2000) 1.08
An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription. Cell Host Microbe (2012) 1.08
Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanism. Mol Cell Biol (1999) 1.07
The histone chaperone protein Nucleosome Assembly Protein-1 (hNAP-1) binds HIV-1 Tat and promotes viral transcription. Retrovirology (2008) 1.06
The growth factor granulin interacts with cyclin T1 and modulates P-TEFb-dependent transcription. Mol Cell Biol (2003) 1.05
Roles and functions of HIV-1 Tat protein in the CNS: an overview. Virol J (2013) 0.99
Cross-talk among RNA polymerase II kinases modulates C-terminal domain phosphorylation. J Biol Chem (2012) 0.97
Transition step during assembly of HIV Tat:P-TEFb transcription complexes and transfer to TAR RNA. Mol Cell Biol (2012) 0.95
Cyclin T1/CDK9 interacts with influenza A virus polymerase and facilitates its association with cellular RNA polymerase II. J Virol (2010) 0.94
Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity. J Virol (2012) 0.94
Mapping the architecture of the HIV-1 Tat circuit: A decision-making circuit that lacks bistability and exploits stochastic noise. Methods (2010) 0.93
Binding of Tat to TAR and recruitment of positive transcription elongation factor b occur independently in bovine immunodeficiency virus. J Virol (2000) 0.90
Replication of human immunodeficiency viruses engineered with heterologous Tat-transactivation response element interactions. J Virol (2003) 0.90
Optimized chimeras between kinase-inactive mutant Cdk9 and truncated cyclin T1 proteins efficiently inhibit Tat transactivation and human immunodeficiency virus gene expression. J Virol (2002) 0.88
Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors. Virology (2011) 0.88
Ubiquitylation of Cdk9 by Skp2 facilitates optimal Tat transactivation. J Virol (2005) 0.87
A minimal chimera of human cyclin T1 and tat binds TAR and activates human immunodeficiency virus transcription in murine cells. J Virol (2002) 0.87
Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription. Antimicrob Agents Chemother (2004) 0.87
Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection. J Virol (2015) 0.85
Selection of TAR RNA-binding chameleon peptides by using a retroviral replication system. J Virol (2004) 0.85
Human cyclin T1 expression ameliorates a T-cell-specific transcriptional limitation for HIV in transgenic rats, but is not sufficient for a spreading infection of prototypic R5 HIV-1 strains ex vivo. Retrovirology (2009) 0.84
High natural permissivity of primary rabbit cells for HIV-1, with a virion infectivity defect in macrophages as the final replication barrier. J Virol (2010) 0.84
Activation of P-TEFb at sites of dual HIV/TB infection, and inhibition of MTB-induced HIV transcriptional activation by the inhibitor of CDK9, Indirubin-3'-monoxime. AIDS Res Hum Retroviruses (2011) 0.83
Genetic analysis of the structure and function of 7SK small nuclear ribonucleoprotein (snRNP) in cells. J Biol Chem (2014) 0.83
Human topoisomerase I promotes HIV-1 proviral DNA synthesis: implications for the species specificity and cellular tropism of HIV-1 infection. Proc Natl Acad Sci U S A (2003) 0.80
Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication. J Virol (2013) 0.79
A single point mutation in cyclin T1 eliminates binding to Hexim1, Cdk9 and RNA but not to AFF4 and enforces repression of HIV transcription. Retrovirology (2014) 0.79
FACT Proteins, SUPT16H and SSRP1, Are Transcriptional Suppressors of HIV-1 and HTLV-1 That Facilitate Viral Latency. J Biol Chem (2015) 0.79
Molecular dynamics simulation and experimental verification of the interaction between cyclin T1 and HIV-1 Tat proteins. PLoS One (2015) 0.78
The Smad3/Smad4/CDK9 complex promotes renal fibrosis in mice with unilateral ureteral obstruction. Kidney Int (2015) 0.78
BRCA1 functions as a novel transcriptional cofactor in HIV-1 infection. Virol J (2015) 0.76
Polo-like kinase 1 inhibits the activity of positive transcription elongation factor of RNA Pol II b (P-TEFb). PLoS One (2013) 0.76
Development of temperature-sensitive mutants of the Drosophila melanogaster P-TEFb (Cyclin T/CDK9) heterodimer using yeast two-hybrid screening. Biochem Biophys Res Commun (2013) 0.75
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res (1983) 124.30
Transcriptional activation by recruitment. Nature (1997) 10.44
Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature (1988) 10.15
A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell (1998) 10.14
The C-terminal domain of RNA polymerase II couples mRNA processing to transcription. Nature (1997) 8.86
Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev (1997) 6.88
Purification of P-TEFb, a transcription factor required for the transition into productive elongation. J Biol Chem (1995) 5.31
P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev (1997) 5.13
Identification of multiple cyclin subunits of human P-TEFb. Genes Dev (1998) 4.73
Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem (1994) 4.70
Phosphorylation of RNA polymerase II C-terminal domain and transcriptional elongation. Nature (1994) 4.57
The C-terminal domain of the largest subunit of RNA polymerase II interacts with a novel set of serine/arginine-rich proteins. Proc Natl Acad Sci U S A (1996) 4.16
Recycling of the general transcription factors during RNA polymerase II transcription. Genes Dev (1995) 3.88
Transcription factors IIE and IIH and ATP hydrolysis direct promoter clearance by RNA polymerase II. Cell (1994) 3.61
Transcription elongation and eukaryotic gene regulation. Oncogene (1990) 3.34
Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature (1996) 2.92
TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc Natl Acad Sci U S A (1997) 2.52
Transcriptional antitermination. Nature (1993) 2.52
Requirement for TFIIH kinase activity in transcription by RNA polymerase II. Nature (1995) 2.43
The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev (1997) 2.38
Pre-mRNA processing and the CTD of RNA polymerase II: the tail that wags the dog? Cell (1997) 2.35
The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence. Genes Dev (1992) 2.24
Purification of a Tat-associated kinase reveals a TFIIH complex that modulates HIV-1 transcription. EMBO J (1997) 2.20
Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function. J Virol (1993) 2.16
Regulation of transcriptional elongation by RNA polymerase II. Curr Opin Genet Dev (1995) 2.03
The CDC2-related kinase PITALRE is the catalytic subunit of active multimeric protein complexes. Biochem J (1996) 1.83
The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme. Mol Cell Biol (1997) 1.70
Inhibition of human immunodeficiency virus type 1 Tat activity by coexpression of heterologous trans activators. J Virol (1992) 1.68
TFIIH functions in regulating transcriptional elongation by RNA polymerase II in Xenopus oocytes. Mol Cell Biol (1996) 1.54
The RNA polymerase II elongation complex. FASEB J (1995) 1.28
Functional analysis of interactions between Tat and the trans-activation response element of human immunodeficiency virus type 1 in cells. J Virol (1993) 1.24
Association of Tat with purified HIV-1 and HIV-2 transcription preinitiation complexes. J Biol Chem (1997) 1.17
Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. Cancer Res (1995) 1.06
Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Gene Ther (1995) 0.97
A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis (1995) 0.94
Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region. Gene Ther (1996) 0.93
Progress in anti-HIV structure-based drug design. Trends Biotechnol (1995) 0.87
Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature (1988) 10.15
Phytochrome A null mutants of Arabidopsis display a wild-type phenotype in white light. Plant Cell (1993) 7.51
Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev (1997) 6.88
Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J Biol Chem (1996) 6.78
Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus. Proc Natl Acad Sci U S A (1986) 6.57
Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem (2001) 5.36
Purification of P-TEFb, a transcription factor required for the transition into productive elongation. J Biol Chem (1995) 5.31
P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev (1997) 5.13
Identification of multiple cyclin subunits of human P-TEFb. Genes Dev (1998) 4.73
Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem (1994) 4.70
Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat. Genes Dev (1989) 4.63
NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell (2001) 4.55
Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature (2000) 4.31
P-TEFb kinase recruitment and function at heat shock loci. Genes Dev (2000) 4.07
Intervening sequence of DNA identified in the structural portion of a mouse beta-globin gene. Proc Natl Acad Sci U S A (1978) 4.02
Control of formation of two distinct classes of RNA polymerase II elongation complexes. Mol Cell Biol (1992) 3.60
Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. Proc Natl Acad Sci U S A (1987) 3.47
NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein. Neuron (2000) 3.45
Trans-activation by HIV-1 Tat via a heterologous RNA binding protein. Cell (1990) 3.27
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem (2000) 3.13
Structure--function relationships in HIV-1 Nef. EMBO Rep (2001) 2.87
A highly purified RNA polymerase II elongation control system. J Biol Chem (2001) 2.84
Trans-activation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein. Proc Natl Acad Sci U S A (1988) 2.79
In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother (2002) 2.66
HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization. Immunity (1994) 2.63
Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. Mol Cell Biol (2000) 2.58
Human immunodeficiency virus type 1 Nef associates with a cellular serine kinase in T lymphocytes. Proc Natl Acad Sci U S A (1994) 2.48
Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity (2000) 2.47
The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev (1997) 2.38
Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique (2003) 2.25
Fractionation of transcription factors for RNA polymerase II from Drosophila Kc cell nuclear extracts. J Biol Chem (1987) 2.23
Signaling through T lymphocyte surface proteins, TCR/CD3 and CD28, activates the HIV-1 long terminal repeat. J Immunol (1989) 2.21
Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development (1999) 2.20
Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc Natl Acad Sci U S A (1994) 2.14
Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions. Mol Cell (1999) 2.09
Endocytic entry of HIV-1. Curr Biol (2000) 2.08
Interactions between HIV1 Nef and vacuolar ATPase facilitate the internalization of CD4. Immunity (1998) 2.08
Cyclin K functions as a CDK9 regulatory subunit and participates in RNA polymerase II transcription. J Biol Chem (1999) 2.05
Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. Oncogene (1993) 1.99
Gibberellin: inhibitor of an inhibitor of...? Bioessays (1998) 1.97
Enhanced efficiency of quantitative trait loci mapping analysis based on multivariate complexes of quantitative traits. Genetics (2001) 1.89
Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T. Proc Natl Acad Sci U S A (1999) 1.87
Prospective randomized trial comparing conventional laparoscopic colectomy with hand-assisted laparoscopic colectomy: applicability, immediate clinical outcome, inflammatory response, and cost. Surg Endosc (2001) 1.86
The CDC2-related kinase PITALRE is the catalytic subunit of active multimeric protein complexes. Biochem J (1996) 1.83
Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene (1998) 1.82
Activation of PAK by HIV and SIV Nef: importance for AIDS in rhesus macaques. Curr Biol (1996) 1.81
Identification of a cyclin subunit required for the function of Drosophila P-TEFb. J Biol Chem (1998) 1.77
Risk factors associated with the prevalence of pulmonary tuberculosis among sanitary workers in Shanghai. Tubercle (1988) 1.72
Drosophila RNA polymerase II elongation factor DmS-II has homology to mouse S-II and sequence similarity to yeast PPR2. Nucleic Acids Res (1990) 1.72
Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation. Virology (1999) 1.70
The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme. Mol Cell Biol (1997) 1.70
B-cell-specific and interferon-gamma-inducible regulation of the HLA-DR alpha gene. Proc Natl Acad Sci U S A (1988) 1.70
Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells. J Virol (1992) 1.69
The 3' end of drosophila histone H3 mRNA is produced by a processing activity in vitro. Cell (1984) 1.69
Rh type B glycoprotein is a new member of the Rh superfamily and a putative ammonia transporter in mammals. J Biol Chem (2001) 1.69
Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II. Proc Natl Acad Sci U S A (1996) 1.68
Inhibition of human immunodeficiency virus type 1 Tat activity by coexpression of heterologous trans activators. J Virol (1992) 1.68
The human immunodeficiency virus type 1 long terminal repeat specifies two different transcription complexes, only one of which is regulated by Tat. J Virol (1993) 1.67
Cell cycle-dependent phosphorylation of the retinoblastoma-related protein p130. Oncogene (1995) 1.65
Nef increases infectivity of HIV via lipid rafts. Curr Biol (2001) 1.64
Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Blood (1996) 1.63
The N-terminus of Nef from HIV-1/SIV associates with a protein complex containing Lck and a serine kinase. Immunity (1997) 1.61
Upregulation of cyclin T1/CDK9 complexes during T cell activation. Oncogene (1998) 1.57
Structure and regulation of the CDK5-p25(nck5a) complex. Mol Cell (2001) 1.57
Cellular protein modulates effects of human immunodeficiency virus type 1 Rev. J Virol (1994) 1.56
A conserved domain and membrane targeting of Nef from HIV and SIV are required for association with a cellular serine kinase activity. J Biol Chem (1995) 1.53
Stability of Drosophila RNA polymerase II elongation complexes in vitro. Mol Cell Biol (1992) 1.53
CDC42 and Rac1 are implicated in the activation of the Nef-associated kinase and replication of HIV-1. Curr Biol (1996) 1.52
Mutational analysis of the DRA promoter: cis-acting sequences and trans-acting factors. Mol Cell Biol (1990) 1.52
Regulation of expression of the human interferon gamma gene. Proc Natl Acad Sci U S A (1985) 1.51
Properties of a Drosophila RNA polymerase II elongation factor. J Biol Chem (1989) 1.49
Cytomegalovirus activates transcription directed by the long terminal repeat of human immunodeficiency virus type 1. J Virol (1990) 1.49
Low section of the rectum during laparoscopic total mesorectal excision using the Contour device. Technical report. Surg Endosc (2006) 1.48
Expression of Arabidopsis GAI in transgenic rice represses multiple gibberellin responses. Plant Cell (2001) 1.48
Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes. Mol Cell Biol (1999) 1.46
Plant GRAS and metazoan STATs: one family? Bioessays (2000) 1.42
Mechanism of DmS-II-mediated pause suppression by Drosophila RNA polymerase II. J Biol Chem (1993) 1.41
Purification of an RNA polymerase II transcript release factor from Drosophila. J Biol Chem (1996) 1.36
p21-activated kinase 1 plays a critical role in cellular activation by Nef. Mol Cell Biol (2000) 1.35
The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32. Nucleic Acids Res (1997) 1.32
Action of alpha-amanitin during pyrophosphorolysis and elongation by RNA polymerase II. J Biol Chem (1995) 1.28
Microsatellite diversity correlated with ecological-edaphic and genetic factors in three microsites of wild emmer wheat in North Israel. Mol Biol Evol (2000) 1.27
Mutant human B cell lines deficient in class II major histocompatibility complex transcription. J Immunol (1987) 1.24
Substrate recognition through a PDZ domain in tail-specific protease. Biochemistry (2000) 1.24
Functional analysis of interactions between Tat and the trans-activation response element of human immunodeficiency virus type 1 in cells. J Virol (1993) 1.24
Transcriptional enhancers in the HLA-DQ subregion. Mol Cell Biol (1987) 1.24
Immunoglobulin gamma 1 heavy chain gene: structural gene sequences cloned in a bacterial plasmid. Gene (1980) 1.23
Are lignins optically active? J Agric Food Chem (1999) 1.22